Back to all studies
🧴
Phase 3
Dermatology
in-person
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Du…
Sponsored by AbbVie
Compensation
$500–$2,500
Duration
3 months
Location
Nationwide
About this study
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD. Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This st…
Who can participate
- • Adults aged 18–63
- • All genders welcome
- • Diagnosed with or experiencing atopic dermatitis
- • Able to attend in-person clinic visits
What's included
- • Compensation up to $2,500
- • All study-related medical care at no cost
- • Lab work, screenings, and physician consultations
- • Study medication or treatment provided
IRB-approved study. Free to apply. Your information is kept confidential.
Ready to Find a Paid Study?
Join over 100,000 people who have been matched with clinical studies. It's free, fast, and could change your life.